About

Simon Dixon is a leading urological surgeon and researcher whose work is redefining surgical standards for bladder cancer. His primary research focuses on radical cystectomy, comparing robot-assisted techniques with traditional open surgery to improve patient recovery and outcomes. Dixon is best known as the chief investigator of the landmark iROC trial, a randomized controlled study that demonstrated robot-assisted radical cystectomy with intracorporeal urinary diversion significantly reduces 90-day morbidity and hospital stays compared to open surgery. This pivotal work, published in 2022, has already amassed over 320 citations, reflecting its profound impact on clinical practice. He has also led critical cost-effectiveness analyses showing that the robotic approach offers value to healthcare payers. Beyond the operating room, Dixon explores innovative preoperative assessment tools, including wearable devices and cardiopulmonary exercise testing, to predict complications. His contributions have not only advanced surgical technique but have provided high-quality evidence that is shaping international guidelines for bladder cancer management.

Research Focus

Key Achievements

5
H-Index
5
Papers
464
Total Citations
93
Avg Citations/Paper
🏆 Most Cited Paper
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer
320 citations · 2022
📈 Most Prolific Year: 2018 (2 Papers)
🤝 Key Collaborators: 77
🏛 Institutions: University of Sheffield, Decision Sciences (United States), University of the Witwatersrand, Sheffield Hallam University, Age UK

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago